A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy

被引:71
|
作者
Hurria, Arti
Hurria, Anju
Zuckerman, Enid
Panageas, Katherine S.
Fornier, Monica
D'Andrea, Gabriella
Dang, Chau
Moasser, Mark
Robson, Mark
Seidman, Andrew
Currie, Violante
VanPoznak, Catherine
Theodoulou, Maria
Lachs, Mark S.
Hudis, Clifford
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA
[2] SUNY Upstate Med Univ, Syracuse, NY USA
[3] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[4] Cornell Univ, Weill Med Coll, Dept Med, Ithaca, NY USA
关键词
geriatric assessment; adjuvant chemotherapy; breast cancer; toxicity;
D O I
10.1111/j.1532-5415.2006.00789.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES: To examine the toxicity experienced by a cohort of older women receiving adjuvant chemotherapy for breast cancer and the longitudinal effect on their functional status and quality of life (QOL). DESIGN: A geriatric assessment measuring functional status, comorbidity, mood, nutritional status, and QOL was performed before chemotherapy, at the end of chemotherapy, and 6 months later. SETTING: This prospective longitudinal study was conducted at Memorial Sloan-Kettering Cancer Center, New York, New York. PARTICIPANTS: Fifty patients aged 65 and older with Stage I to III breast cancer receiving any adjuvant chemotherapy; 49 were evaluable. MEASUREMENTS: The chemotherapy regimen and the toxicity to chemotherapy were recorded. A geriatric assessment was performed before the start of chemotherapy, on completion of chemotherapy, and 6 months after completion of chemotherapy. QOL testing was performed at the same times. RESULTS: Patients (mean age 68, range 65-84) received an anthracycline-based chemotherapy regimen (n = 15) or cyclophosphamide 600 mg/m(2) intravenously (IV), methotrexate 40 mg/m(2) IV, 5-fluorouracil 600 mg/m(2) IV every 3 weeks for eight cycles (n = 34). Grade 3 or 4 toxicity occurred in 53% (n = 26), hematological toxicity in 27% (n = 13), and nonhematological toxicity in 31% (n = 15). Despite toxicity, there was no significant longitudinal change in functional status or QOL. CONCLUSION: Despite toxicity from adjuvant chemotherapy, this cohort of relatively young older patients maintained their functional status and QOL from before chemotherapy to 6 months postchemotherapy. Subtle changes in higher-order functioning would require assessment using different geriatric assessment tools.
引用
收藏
页码:1119 / 1124
页数:6
相关论文
共 50 条
  • [31] Quality of life after adjuvant chemotherapy for breast cancer
    Jo Ann Broeckel
    Paul B. Jacobsen
    Lodovico Balducci
    John Horton
    Gary H. Lyman
    Breast Cancer Research and Treatment, 2000, 62 : 141 - 150
  • [32] Quality of life following adjuvant chemotherapy for breast cancer
    Broeckel, JA
    Lyman, GH
    Jacobsen, PB
    PSYCHOSOMATIC MEDICINE, 1998, 60 (01): : 120 - 120
  • [33] Quality of life after adjuvant chemotherapy for breast cancer
    Broeckel, JA
    Jacobsen, PB
    Balducci, L
    Horton, J
    Lyman, GH
    BREAST CANCER RESEARCH AND TREATMENT, 2000, 62 (02) : 141 - 150
  • [34] Predicting postoperative complications and their impact on quality of life and functional status in older patients with breast cancer
    Lemij, A. A.
    Van der Plas-Krijgsman, W. G.
    Bastiaannet, E.
    Merkus, J. W. S.
    van Dalen, T.
    Vulink, A. J. E.
    van Gerven, L.
    Guicherit, O. R.
    Linthorst-Niers, E. M. H.
    Lans, T. E.
    van der Pol, C. C.
    Wyld, L.
    Morgan, J. L.
    Portielje, J. E. A.
    de Glas, N. A.
    Liefers, G. J.
    BRITISH JOURNAL OF SURGERY, 2022, 109 (07) : 595 - 602
  • [35] Longitudinal prospective assessment of sleep quality: before, during, and after adjuvant chemotherapy for breast cancer
    Stacy D. Sanford
    Lynne I. Wagner
    Jennifer L. Beaumont
    Zeeshan Butt
    Jerry J. Sweet
    David Cella
    Supportive Care in Cancer, 2013, 21 : 959 - 967
  • [36] Longitudinal prospective assessment of sleep quality: before, during, and after adjuvant chemotherapy for breast cancer
    Sanford, Stacy D.
    Wagner, Lynne I.
    Beaumont, Jennifer L.
    Butt, Zeeshan
    Sweet, Jerry J.
    Cella, David
    SUPPORTIVE CARE IN CANCER, 2013, 21 (04) : 959 - 967
  • [37] Is adjuvant chemotherapy necessary in older patients with breast cancer?
    Midori Morita
    Akihiko Shimomura
    Emi Tokuda
    Yoshiya Horimoto
    Yukino Kawamura
    Yumiko Ishizuka
    Katsutoshi Sekine
    Sayaka Obayashi
    Yuki Kojima
    Yukari Uemura
    Toru Higuchi
    Breast Cancer, 2022, 29 : 498 - 506
  • [38] Is adjuvant chemotherapy necessary in older patients with breast cancer?
    Morita, Midori
    Shimomura, Akihiko
    Tokuda, Emi
    Horimoto, Yoshiya
    Kawamura, Yukino
    Ishizuka, Yumiko
    Sekine, Katsutoshi
    Obayashi, Sayaka
    Kojima, Yuki
    Uemura, Yukari
    Higuchi, Toru
    BREAST CANCER, 2022, 29 (03) : 498 - 506
  • [39] Adjuvant Chemotherapy for Breast Cancer in Older Adult Patients
    Gao, Ying
    Hao, Jie
    Zhang, Zhendong
    CLINICAL INTERVENTIONS IN AGING, 2024, 19 : 1281 - 1286
  • [40] Effect of Creatinine Clearance on Patterns of Toxicity in Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer
    Arti Hurria
    Anju Hurria
    Kelly Brogan
    Katherine S. Panageas
    Carol Pearce
    Larry Norton
    Ann Jakubowski
    Jane Howard
    Clifford Hudis
    Drugs & Aging, 2005, 22 : 785 - 791